SS-31, also known as elamipretide, now carries an FDA approval under the brand name FORZINITY for Barth syndrome, yet the "SS-31" sold on the research-peptide market is a separate, unapproved product with no legitimate consumer price. Every dollar figure attached to a research vial comes from that unregulated market, where listings run from the low tens of dollars to well over one hundred per vial and a bargain price signals danger rather than value.
On the research-peptide market SS-31 sells for roughly the low tens of dollars to over one hundred dollars per vial, while the only characterized elamipretide reaches patients through the FDA-approved FORZINITY prescription for Barth syndrome or a registered clinical trial.
Across the research-peptide market a single SS-31 vial generally lists somewhere between the low tens of dollars and a bit over one hundred, with most sitting in a broad middle band. The labeled milligram content is the single largest lever on that figure, and checkout costs such as shipping, cold-pack upsells, and payment surcharges push the real outlay above the headline number.
A single research-market SS-31 vial generally lists between the low tens of dollars and just over one hundred dollars, with the labeled milligram content driving most of that spread rather than any measured quality.
In a market with no independent testing, the only reliable way for a seller to price below the rest is to spend less on what goes into the vial. Sourcing reviews of this market report that a price well under the common band tracks with underfilling, degraded batches, skipped purification, or substitution of a cheaper peptide, so the apparent discount marks the corners that remove a buyer's protection.
In an untested market the cheapest way for a seller to reach a below-market price is to reduce, degrade, or substitute the vial's contents, so an unusually low SS-31 price tracks with underdosed, impure, or wrong product rather than value.
Genuine, identity-confirmed elamipretide reaches a person through two regulated channels rather than a marketplace. For Barth syndrome it is the FDA-approved FORZINITY, obtained on a prescription and dispensed by a pharmacy; for the uses that remain investigational it is available only by enrolling in a registered clinical trial under medical supervision, and in both the material is made to pharmaceutical standards with identity, dose, and purity documented rather than claimed.
| Criteria | FORZINITY (approved) | Registered clinical trial |
|---|---|---|
| Regulatory status | FDA-approved for Barth syndrome | Investigational, non-approved uses |
| Access path | Prescription from a licensed prescriber | Enrollment and eligibility screening |
| Material standard | Pharmaceutical manufacturing, documented | Pharmaceutical manufacturing, documented |
| Oversight | Pharmacy dispensing, prescriber monitoring | Informed consent, clinical monitoring |
Genuine elamipretide is available through only two legitimate channels, the FDA-approved FORZINITY prescription for Barth syndrome and enrollment in a registered clinical trial for investigational uses, both supplying pharmaceutical-grade material under documented medical oversight.
On a research-market listing the label sets the price, because the milligram figure and the purity percentage are the two numbers a vendor uses to justify the cost. Both are assertions rather than verified facts, since nothing external confirms the powder matches the print, and a certificate of analysis offered as proof can be fabricated, reused from another batch, or unrelated to the vial actually shipped.
On the research market the labeled milligram amount and purity percentage set the price, but because nothing external verifies either number, a higher price bought on impressive label claims buys only a more expensive version of the same uncertainty.
Buying SS-31 online sits in a legally uncomfortable zone because the research-labeled powder is not an FDA-approved medicine, and acquiring an unapproved drug for personal human use falls outside the channels regulators recognize. The research-use-only disclaimers vendors attach read less as honest description than as an attempt to shift responsibility onto a buyer who plainly intends to inject the material.
The research-labeled SS-31 sold online is not the FDA-approved elamipretide product, so acquiring it for human use falls outside approved channels, and research-use-only disclaimers shift responsibility onto a buyer who still carries legal exposure that customs seizure or personal-use intent can bring into the open.
The path into a clinical trial runs through public trial registries, where active and recruiting studies are listed with their locations, the conditions under study, and the criteria for who can join. A treating physician familiar with a person's condition is often the most efficient route, able to point toward a relevant study and interpret whether the fit is genuine, and the record describes a defined sequence rather than a checkout.
Access to elamipretide for investigational uses runs through public trial registries and a treating physician's referral, followed by eligibility screening and informed consent, with the study supplying characterized material and medical monitoring rather than a purchased vial.
Vendor purity and quantity claims cannot be trusted for a structural reason: no independent body stands between seller and buyer to confirm them. Where an approved medicine has regulators and quality systems verifying that the label matches the vial, the research-peptide market omits that entire layer, so a claim is only as good as the seller's word and a certificate of analysis can be fabricated, copied from a better batch, or attached to a vial it never tested.
Research-market purity and quantity figures describe the marketing rather than the contents, because no independent body verifies the label, a certificate of analysis can be fabricated or mismatched, and batch-to-batch variation defeats any single stated purity percentage.
Paying for SS-31 is no guarantee of receiving elamipretide, because several failure points sit between the order and the vial in hand. Substitution with a cheaper peptide, a degraded batch, or inert filler is easy to make and, in an unpoliced market, easy to get away with, and a missing cold chain can break down even an honestly filled vial before it is ever used.
Because substitution, degradation, and a missing cold chain all sit between the order and the vial with no lab check a home buyer can run, paying for research-market SS-31 buys a labeled vial and a hope rather than a verified dose of elamipretide.
Educational use only. This article describes what the published scientific and clinical literature reports about SS-31. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
